Jo Hughes, PA
Physician Assistant · Greensboro, NCNPI 1265663371
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $645,888 of the $814,405 with a category attached, or 79.3%. 34 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 57.1% of the total. 2025 is the largest year on record at $270,912, 5.2 times the $51,752 reported in 2021. Among physician assistant clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,613 payments — averaging $504.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$465K
- Alkermes, Inc.$132K
- AbbVie$77K
- Supernus Pharmaceuticals, Inc.$69K
- Axsome Therapeutics, Inc.$36K
- E.r. Squibb & Sons, L.L.C.$11K
- plus $24K from 28 others
What the payments were for
- Consulting fees$55,0277%
- Speaking & faculty fees$645,88879%
- Travel & lodging$80,67910%
- Food & beverage$32,7114%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$472,517
- INGREZZA$456,496
- VRAYLAR$71,293
- QELBREE$66,462
- ARISTADA$35,912
- Auvelity$34,377
- Fanapt$8,842
- COBENFY$8,104
- UZEDY$3,800
- ARISTADA INITIO$3,738
- SPRAVATO$1,112
- Equetro$466
- CAPLYTA$350
- SUNOSI$125
- Quillichew ER$123
- Dyanavel XR$123
- Quillivant$123
- AUSTEDO$115
- Zurzuvae$100
How this compares
$814,405 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 34 | $311,316 |
| Abilify MaintenaAripiprazole | 25 | $80,589 |
| VraylarCariprazine Hcl | 43 | $68,284 |
| AristadaAripiprazole Lauroxil | 25 | $65,077 |
| LybalviOlanzapine/Samidorphan Malate | 29 | $52,133 |
| NuedextaDextromethorphan Hbr/Quinidine | 24 | $34,458 |
| Invega SustennaPaliperidone Palmitate | 11 | $26,815 |
| VyvanseLisdexamfetamine Dimesylate | 25 | $11,935 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 47 | $11,893 |
| TrintellixVortioxetine Hydrobromide | 21 | $10,932 |
| QelbreeViloxazine Hcl | 15 | $10,622 |
| LinzessLinaclotide | 12 | $6,399 |
| BelsomraSuvorexant | 12 | $5,397 |
| Asenapine Maleate | 18 | $4,245 |
| Clozapine | 61 | $3,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $465,365 | $311,31634 claims |
| Alkermes, Inc.Aristada, Lybalvi | $132,025 | $117,21054 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $365 | $80,58925 claims |
| AbbVieVraylar, Linzess | $77,183 | $74,68355 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $13 | $34,45824 claims |
| Johnson & JohnsonInvega Sustenna | $442 | $26,81511 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $124 | $22,86646 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $69,253 | $10,62215 claims |
| MerckBelsomra | $92 | $5,39712 claims |
| Almatica Pharma LLCSertraline Hcl | $42 | $863149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Greensboro
- Erin GrayGreensboro$118K
- Kayla McKenzieGreensboro$56K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.